17th Oct 2014 14:48
LONDON (Alliance News) - Tissue Regenix Group PLC said Friday that it has seen positive initial results from its clinical study into the efficacy of its DermaPure wound treatment, and will present these results at the Symposium on Advanced Wound Care in Las Vegas.
Although the findings are still to be peer reviewed and verified, early findings suggest that DermaPure results in higher growth of new blood vessels to aid wound care, and showed elevated mRNA expression of PROK2 and MT6-MMP, suggesting it could improve cellular level healing compared to a control sample, the company said.
DermaPure is a skin substitute that works by taking donor skin and removing DNA and cells using the company's dCELL process to leave a natural scaffold that can be placed in the wound and aid natural healing.
Results from a trial into the efficacy of DermaPure in treating chronic wounds will also be presented at the Symposium.
The company said that commercialisation of DermaPure "continues to progress according to plan." It is working on further hospital product evaluation committee approvals, and progressing the enrolment of patients into human trials in the US.
Shares in Tissue Regenix are trading down 1.8% at 22.10 pence Friday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group